The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Open accessAbstract
Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder with dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in the U.S. are living with AD and by 2050 this number is expected to double resulting in a significant socio-economic burden. Despite intensive research, the exact mechanisms that trigger AD are still not known and at the present there is no cure for it. In recent years, many signaling pathways associated with AD neuropathology have been explored as possible candidate targets for the treatment of this condition including glycogen synthase kinase-3β (GSK3-β). GSK3-β is considered a key player in AD pathophysiology since dysregulation of this kinase influences all the major hallmarks of the disease including: tau phosphorylation, amyloid-β production, memory, neurogenesis and synaptic function. The present review summarizes the current understanding of the GSK3-β neurobiology with particular emphasis on its effects on specific signaling pathways associated with AD pathophysiology. Moreover, it discusses the feasibility of targeting GSK3-β for AD treatment and provides a summary of the current research effort to develop GSK3-β inhibitors in preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Beside Aβ and tau aggregation, neuroinflammation is another major feature of the AD brain pathology (Figure 1) [60,61].”
BackgroundCell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis
Gumbiner, B. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81279-9 · Cited by 3,471
Mechanisms and Functional Implications of Adult Neurogenesis
Zhao, C., Deng, W., & Gage, F. H. (2008) · Cell · doi:10.1016/j.cell.2008.01.033 · Cited by 3,007
Moreno-Jiménez, E. P., Flor-García, M., Terreros-Roncal, J., Rábano, A., Cafini, F., Pallas-Bazarra, N., Ávila, J., & Llorens-Martín, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0375-9 · Cited by 1,577 · cited 1×
“Neurogenesis is a dynamic process required for memory consolidation and pattern separation and is altered in the CNS of AD patients and animal models of the disease [56,57].”
BackgroundGSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 3×
“Tideglusib has been tested in two small Phase II clinical trials in patients with mild to moderate AD, which showed good tolerability but no significant clinical improvements [77].”
BackgroundLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Embi, N., Rylatt, D. B., & Cohen, P. (1980) · PubMed · Cited by 911
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
EMBI, N., RYLATT, D. B., & COHEN, P. (1980) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1980.tb06059.x · Cited by 779
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.029 · Cited by 695
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons
Hong, M., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19547 · Cited by 522
Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium
Ryves, W. J., & Harwood, A. J. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4169 · Cited by 493
Jackson, G. R., Wiedau-Pazos, M., Sang, T.-K., Wagle, N., Brown, C. A., Massachi, S., & Geschwind, D. H. (2002) · Neuron · doi:10.1016/s0896-6273(02)00706-7 · Cited by 488
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
Chen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000149 · Cited by 433
Regulation of cell–cell adhesion by the cadherin–catenin complex
Nelson, W. J. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360149 · Cited by 412
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Leroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404
Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., & Imahori, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81066-9 · Cited by 402
Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway
Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00629 · Cited by 401
Machado‐Vieira, R., Manji, H. K., & Zarate Jr, C. A. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00714.x · Cited by 370
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
GSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation
Hooper, C., Markevich, V., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernandez, F., Anderton, B., Rosenblum, K., Bliss, T., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05245.x · Cited by 344
Murase, S., Mosser, E., & Schuman, E. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00764-x · Cited by 341
Kurochkin, I. V., & Goto, S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00387-4 · Cited by 340
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327 · cited 2×
“Moreover, Aβ can disrupt the normal Wnt pathway activity that prevents Wnt from inhibiting the GSK3-β [32], and directly activate GSK3- β which will then promote tau phosphorylation [33].”
BackgroundTakashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., & Masliah, E. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21787 · Cited by 287
dos Santos Picanco, L. C., Ozela, P. F., de Fatima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga, F. S., de Paula da Silva, C. H. T., dos Santos, C. B. R., Rosa, J. M. C., & da Silva Hage-Melim, L. I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867323666161213101126 · Cited by 284
KOIKE, H., Tomioka, S., Sorimachi, H., Saido, T. C., Maruyama, K., Okuyama, A., Fujisawa‐Sehara, A., Ohno, S., Suzuki, K., & Ishiura, S. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3430371 · Cited by 278
Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease
Crouch, P. J., Harding, S.-M. E., White, A. R., Camakaris, J., Bush, A. I., & Masters, C. L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.013 · Cited by 244
Yuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240 · cited 1×
“For example, treatment of BV-2 microglia cells with GSK3 inhibitors has been shown to significantly reduce microglia migration in vitro, in a transwell migration assay [67].”
MethodAvrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., & Eldar-Finkelman, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409250 · Cited by 231
Magdesian, M. H., Carvalho, M. M. V. F., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 221
Caccamo, A., Oddo, S., Tran, L. X., & LaFerla, F. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061178 · Cited by 217
Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3
Beurel, E., & Jope, R. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802481200 · Cited by 190
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Eikelenboom, P., & van Gool, W. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0055-1 · Cited by 182
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model
Pérez, M., Hernández, F., Lim, F., Díaz-Nido, J., & Avila, J. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5405 · Cited by 180
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice
Kaidanovich-Beilin, O., Lipina, T. V., Takao, K., van Eede, M., Hattori, S., Laliberté, C., Khan, M., Okamoto, K., Chambers, J. W., Fletcher, P. J., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-35 · Cited by 177
Hu, S., Begum, A. N., Jones, M. R., Oh, M. S., Beech, W. K., Beech, B. H., Yang, F., Chen, P., Ubeda, O. J., Kim, P. C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.007 · Cited by 174
The genetics of Alzheimer's disease
Bagyinszky, E., Youn, Y. C., An, S., & Kim, S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s51571 · Cited by 173
GSK‐3: A key player in neurodegeneration and memory
Giese, K.-P. (2009) · IUBMB Life · doi:10.1002/iub.187 · Cited by 167
Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161
Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100
Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.-M., Yamaguchi, H., & Takashima, A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02583-6 · Cited by 161
Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo
Morales-Garcia, J. A., Luna-Medina, R., Alonso-Gil, S., Sanz-SanCristobal, M., Palomo, V., Gil, C., Santos, A., Martinez, A., & Perez-Castillo, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300110c · Cited by 161
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Cai, Z., Zhao, Y. C., & Zhao, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512802455386 · Cited by 156
Vallée, A., & Lecarpentier, Y. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00459 · Cited by 153
β-catenin is required for memory consolidation
Maguschak, K. A., & Ressler, K. J. (2008) · Nature Neuroscience · doi:10.1038/nn.2198 · Cited by 145
Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain
Soutar, M. P. M., Kim, W.-Y., Williamson, R., Peggie, M. W., Hastie, C. J., McLauchlan, H., Snider, W. D., Gordon‐Weeks, P. R., & Sutherland, C. D. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06988.x · Cited by 139
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies
Medina, M., Garrido, J. J., & Wandosell, F. G. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00024 · Cited by 135
Glycogen synthase kinase 3β links neuroprotection by 17β-estradiol to key Alzheimer processes
Goodenough, S., Schleusner, D., Pietrzik, C. U., Skutella, T., & Behl, C. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.029 · Cited by 135
GSK3β Activity Modifies the Localization and Function of Presenilin 1
Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Andō, K., Shimohama, S., & Kinoshita, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610708200 · Cited by 124
Nakashima, H., Ishihara, T., Suguimoto, S. P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J. Q., Lee, V. M. ‐., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1087-4 · Cited by 122
Zhang, W., Yang, J., Liu, Y., Chen, X., Yu, T., Jia, J., & Liu, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013698 · Cited by 116
Formation of aberrant phosphotau fibrillar polymers in neural cultured cells
Pérez, M., Hernández, F., Gómez‐Ramos, A., Smith, M. A., Perry, G. L., & Ávila, J. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02794.x · Cited by 115
Onishi, T., Iwashita, H., Uno, Y., Kunitomo, J., Saitoh, M., Kimura, E., Fujita, H., Uchiyama, N., Kori, M., & Takizawa, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07532.x · Cited by 106
GSK-3 inhibitors for Alzheimer’s disease
Ávila, J., & Hernández, F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.11.1527 · Cited by 106
Lee, S. J., Chung, Y. H., Joo, K. M., Lim, H. C., Jeon, G. S., Kim, D., Lee, W. B., Kim, Y. S., & Ik, C. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.026 · Cited by 104
The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning?
Bhat, R. V., Andersson, U., Andersson, S., Knerr, L., Bauer, U., & Sundgren‐Andersson, A. K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179934 · Cited by 103
Sirerol‐Piquer, M., Gómez‐Ramos, P., Hernández, F., Pérez, M., Morán, M. A., Fuster-Matanzo, A., Lucas, J. J., Ávila, J., & García‐Verdugo, J. M. (2010) · Hippocampus · doi:10.1002/hipo.20805 · Cited by 91
Ding, Y., Qiao, A., & Fan, G.-H. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.022 · Cited by 76
Glycogen Synthase Kinase‐3β: A Mediator of Inflammation in Alzheimer′s Disease?
Koıstınaho, J., Malm, T., & Goldsteins, G. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/129753 · Cited by 75
Isolation and chromosomal mapping of human glycogen synthase kinase-3 α and -3β encoding genes
Shaw, P., Davies, A. F., Lau, K., Garcia-Barceló, M., Waye, M. M. Y., Lovestone, S., Miller, C. C. J., & Anderton, B. H. (1998) · Genome · doi:10.1139/gen-41-5-720 · Cited by 72
β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer’s disease
Preece, P., Virley, D. J., Costandi, M., Coombes, R., Moss, S. J., Mudge, A. W., JAZIN, E. E., & Cairns, N. J. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00233-x · Cited by 70
Dunning, C. J. R., McGauran, G., Willén, K. I., Gouras, G. K., O’Connell, D. J., & Linse, S. S. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00262 · Cited by 65
Hui, J., Zhang, J., Pu, M., Zhou, X., Dong, L., Mao, X., Shi, G., Zou, J., Wu, J., Jiang, D., et al. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy040 · Cited by 62
Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice
Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.027 · Cited by 59
Cited by
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K., & Ju, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 395
Apoptosis in Alzheimer’s disease: Insight into the signaling pathways and therapeutic avenues
Kumari, S., Dhapola, R., & Reddy, D. H. (2023) · Apoptosis · doi:10.1007/s10495-023-01848-y · Cited by 324
Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110
Metadata
- Authors
- Lauretti, E., Dincer, O., & Praticò, D.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 1867
- Issue
- 5
- Pages
- 118664
- ISSN
- 0167-4889 (ISSN-L)
- OpenAlex
- W3003864134
- Cited by
- 615
- References
- 78
- FWCI
- 30.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.